Join Our Network
Pharmacy / Merchant
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Incepta Pharmaceuticals Ltd. · Tablet
/ Piece
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.
Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Bempedoic Acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowes LDL-C in blood via upregulation of low-density lipoprotein receptors. Ezetimibe is a potent and selective inhibitor of cholesterol absorption that has been shown to reduce the overall delivery of cholesterol to the liver, thereby promoting the synthesis of LDL receptors, with a subsequent reduction of serum LDL-C.
Administer Bempedoic Acid 180 mg & Ezetimibe 10 mg tablet orally once daily with or without food. The safety and effectiveness of this tablet have not been established in pediatric patients.
Simvastatin: Avoid concomitant use of Bempedoic Acid & Ezetimibe with simvastatin greater than 20 mg.Pravastatin: Avoid concomitant use of Bempedoic acid & Ezetimibe with pravastatin greater than 40 mg.
Upper respiratory tract infection
Muscle Spasms
Hyperuricemia
Back pain
Abdominal pain or discomfort
Bronchitis
Pain in extremity
Anemia
Elevated liver enzymes
Discontinue Bempedoic Acid & Ezetimibe when pregnancy is recognized unless the benefits of therapy outweigh the potential risk to the fetus. There are no available data on Bempedoic Acid & Ezetimibe use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There is no information regarding the presence of Bempedoic Acid & Ezetimibe in human or animal milk, the effects of the drug on the breastfeed infant,or the effects of the drug on milk production. Breastfeeding is not recommended during treatment with Bempedoic Acid & Ezetimibe.
Elevations in serum uric acid have occurred. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. Tendon rupture has occurred. Discontinue Bempedoic acid & Ezetimibe at the first sign of tendon rupture. Avoid combination in patients who have a history of tendon disorders or tendon rupture.
Other Anti-anginal & Anti-ischaemic drugs
Do not store above 30°C temperature. Keep away from light and out of the reach of children.